Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.
2.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
3.

Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.

Lee VH, Chan WW, Lee EY, Choy TS, Ho PP, Leung DK, Lam KO, Kwong DL, Leung TW, Khong PL.

Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070.

PMID:
24710123
4.

Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.

Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148. Epub 2012 Jun 12.

PMID:
22692034
5.

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, Horiike A, Yanagitani N, Ohyanagi F, Nishio M.

Cancer Sci. 2015 Nov;106(11):1554-60. doi: 10.1111/cas.12771. Epub 2015 Oct 7.

6.

Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.

Ikushima H, Dong L, Erasmus J, Allen P, McAleer MF, Zhuang Y, Sasaki R, Komaki R.

J Radiat Res. 2010;51(4):465-71. Epub 2010 May 28.

7.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A.

J Clin Oncol. 2013 Oct 20;31(30):3823-30. doi: 10.1200/JCO.2012.47.5947. Epub 2013 Sep 16.

8.

Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE.

Radiat Oncol. 2014 Jan 30;9:41. doi: 10.1186/1748-717X-9-41.

9.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
10.

18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.

Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.

J Nucl Med. 2002 Jan;43(1):39-45.

11.

Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.

Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.

AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.

PMID:
26295651
12.

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.

Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20.

13.

Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.

Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, Zsótér N, Essler M.

Radiat Oncol. 2015 Apr 22;10:100. doi: 10.1186/s13014-015-0407-7.

14.

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14.

15.
16.
17.

Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B.

J Nucl Med. 2014 Oct;55(10):1584-90. doi: 10.2967/jnumed.114.142919. Epub 2014 Sep 11.

18.

Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.

Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1033-9. doi: 10.1016/j.ijrobp.2009.09.081. Epub 2010 May 14.

PMID:
20472359
19.

Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.

Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW Jr.

Lung Cancer. 2012 Dec;78(3):219-24. doi: 10.1016/j.lungcan.2012.08.016. Epub 2012 Sep 23.

PMID:
23009727
20.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640

Supplemental Content

Support Center